<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Phys Ther Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Phys Ther Sci</journal-id><journal-id journal-id-type="publisher-id">JPTS</journal-id><journal-title-group><journal-title>Journal of Physical Therapy Science</journal-title></journal-title-group><issn pub-type="ppub">0915-5287</issn><issn pub-type="epub">2187-5626</issn><publisher><publisher-name>The Society of Physical Therapy Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">jpts-2014-208</article-id><article-id pub-id-type="doi">10.1589/jpts.26.1679</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Relationship among Ocular Diseases, Developmental Levels, and Clinical
Characteristics of Children with Diplegic Cerebral Palsy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Boyaci</surname><given-names>Ahmet</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Akal</surname><given-names>Ali</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tutoglu</surname><given-names>Ahmet</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kandemir</surname><given-names>Hasan</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Koca</surname><given-names>Irfan</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Boyraz</surname><given-names>Ismail</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Celen</surname><given-names>Esra</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ozkan</surname><given-names>Ufuk</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1"><label>1)</label> Department of Physical Medicine and Rehabilitation, Harran
University Medical School, Turkey</aff><aff id="aff2"><label>2)</label> Department of Ophthalmology, Harran University Medical
School, Turkey</aff><aff id="aff3"><label>3)</label> Child and Adolescent Psychiatry, Harran University Medical
School, Turkey</aff><aff id="aff4"><label>4)</label> Department of Physical Medicine and Rehabilitation,
Gaziantep University Medical School, Turkey</aff><aff id="aff5"><label>5)</label> Department of Physical Medicine and Rehabilitation, Abant
Izzet Baysal University Medical School, Turkey</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Ahmet Boyaci, Department of Physical Medicine and Rehabilitation, Harran
University Medical School: Yenisehir Kampusu, Sanliurfa 63300, Turkey. (E-mail: <email xlink:href="drboyaci@hotmail.com">drboyaci@hotmail.com</email>)</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2014</year></pub-date><volume>26</volume><issue>11</issue><fpage>1679</fpage><lpage>1684</lpage><history><date date-type="received"><day>03</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>2014&#x000a9;by the Society of Physical Therapy Science</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p>[Purpose] The aim of this study was to evaluate the relationships among vision problems,
developmental levels, upper extremity functions, and qualities of life of children with
cerebral palsy (CP). [Subjects] The study included 32 children, aged 4&#x02013;15 years, diagnosed
with diplegic type CP. [Methods] Hand function was evaluated using the Manual Ability
Classification System (MACS) and the Bimanual Fine Motor Function (BFMF) scale, and the
severity of CP was assessed using the Gross Motor Function Classification System (GMFCS).
The developmental and mental capabilities of the children were evaluated using the Ankara
Developmental Screening Inventory (ADSI) or the WISC-R test. An oculomotor examination was
conducted for all patients. [Results] Positive correlations were found between GMFCS and
BFMF, GMFCS and MACS, and MACS and BFMF scores (r=0.636; r=0.553; r=0.718, respectively).
Significant correlations were found between upper extremity function, the severity of CP,
the quality of life, and the general developmental level. There was no significant
correlation between ocular disorders and clinical characteristics. [Conclusion] GMFCS,
MACS, and BFMF may be useful for defining the functional status of children with CP, as
they are easy, practical, and simple classification scales that conform to each other.</p></abstract><kwd-group><title>Key words</title><kwd>Gross motor function</kwd><kwd>Ocular disorders</kwd><kwd>Cerebral palsy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Cerebral palsy (CP) is a chronic, non-progressive clinical disease characterised by
movement and posture impairments in children which is associated with permanent brain damage
occurring in the perinatal or natal period<xref rid="r1" ref-type="bibr">1</xref><sup>)</sup>. The patient may be affected by motor, tonus and posture disorders
as well as a wide spectrum of problems associated with cerebral dysfunction such as learning
difficulties, autonomic dysfunction, epilepsy, mental retardation, and sight and hearing
problems<xref rid="r2" ref-type="bibr">2</xref><sup>)</sup>. The prevalence of CP in
Turkey has been stated as 4.4 per 1,000 live births<xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>.</p><p>The most frequently seen type of CP in the Turkish population is diplegic CP, and in 71.6%
of these cases there is a history of prematurity<xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>. Spastic diplegia may be seen in both term and pre-term infants. In
pre-term diplegic CP patients there is often a relationship with periventricular
leukomalacia. Lower extremity involvement is more evident and patients have relatively
better hand functions. According to the severity of the effect, advanced function loss in
the upper extremity may be associated with the degree of spasticity, the presence of
contracture, sensory loss or mental level<xref rid="r4" ref-type="bibr">4</xref><sup>)</sup>.</p><p>Ophthalmological problems are seen in 50&#x02013;90% of CP patients<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref><sup>)</sup>. Within the CP types, it has been reported that ophthalmological
problems occur more often in diplegic type spastic CP<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref><sup>)</sup>. Refractive errors and strabismus are the most often seen
ophthalmological problems in CP<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref><sup>)</sup>. In a study
evaluating the relationship between CP etiology and ocular and visual diseases, it was
reported that particularly for patients with diplegic and triplegic CP with positive
neuroradiological findings together with pre-term patients with low birth-weight, there is a
need for an ophthalmological examination as early as possible<xref rid="r9" ref-type="bibr">9</xref><sup>)</sup>.</p><p>In a study which evaluated the hand functions using the Manual Ability Classification
System (MACS) and the Bimanual Fine Motor Function (BFMF) scale, and the severity of CP with
the Gross Motor Function Classification System (GMFCS), it was reported that in the
evaluation of the hand functions of children with CP, the MACS and BFMF scales are
consistent with each other and with the GMFCS<xref rid="r10" ref-type="bibr">10</xref><sup>)</sup>. Ocular diseases which develop in CP patients and the developmental
level can affect the functional level and quality of life of the patient. To the best of our
knowledge, there is no study in the literature which has researched the relationship of
ocular diseases or developmental level with upper extremity functions, daily living
activities and quality of life of diplegic CP patients. Therefore this study aimed to
evaluate the relationships among visual loss and developmental level, and upper extremity
functions, daily living activities and quality of life.</p></sec><sec sec-type="methods" id="s2"><title>SUBJECTS AND METHODS</title><p>The study group consisted of children with spastic CP who were admitted to the Physical
Medicine and Rehabilitation Clinic between November 2013 and February 2014. The children
included in the study were aged 4&#x02013;15 years and were diagnosed with diplegic CP according to
the Swedish Classification<xref rid="r11" ref-type="bibr">11</xref><sup>)</sup>. Patients
with genetic or metabolic disease and those with a progressive neurological disease were
excluded from the study. Approval for the study was granted by the Institutional Ethics
Committee of Harran University, and written informed consent was obtained from all the
parents of the patients.</p><p>For the determination of the developmental levels and mental capabilities of the children
with CP, the Ankara Developmental Screening Inventory (ADSI), which has been tested for
validity and reliability in Turkey, was used<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref><sup>)</sup>.
The ADSI is a scale which can be used to assess children aged 0&#x02013;6 years to evaluate their
communication-cognitive (CC), fine motor (FM), gross motor (GM), social skills-self care
(SS-SC) and general development (GD) domains. The inventory consists of 154 items which are
answered by the mothers, and responses are given as &#x02018;yes&#x02019;, &#x02018;no&#x02019;, or &#x02018;don&#x02019;t know&#x02019;. The total
score of the test reflects a subject&#x02019;s general developmental level. Those with an average
two standard deviations below the norm are evaluated as developmentally retarded<xref rid="r12" ref-type="bibr">12</xref><sup>)</sup>.</p><p>Children over 6&#x02005;years of age were evaluated with the mental development WISC-R test. For
children who could not be evaluated by the age-appropriate test as they were developmentally
aged below 6&#x02005;years, even though their chronological age was over 6&#x02005;years, the ADSI was
conducted.</p><p>The ophthalmological examinations of all the patients were conducted by the same
ophthalmologist. Refraction errors, fundus examination, slit-lamp biomicroscopic
examination, intraocular pressure measurement and oculomotor examinations were conducted.
Compliance with the tests could not be achieved by any patient in assessment of visual
acuity.</p><p>The GMFCS is a classification system which has been developed for children with CP. It is
separated into 5 levels based on gross motor functions such as starting movements by
oneself, sitting and walking. At Level I, in mobility within the community, disability is
minimal or absent. At Level V, mobility is totally dependent, even with the use of assistive
aids<xref rid="r15" ref-type="bibr">15</xref><sup>)</sup>.</p><p>Hand functions of children with CP while they are holding objects in daily living
activities were evaluated using the MACS scale. The aim is to define the hand performance.
The MACS scale has 5 levels. At Level I, the patient can easily and successfully hold the
objects. At Level V, an object cannot be held by the subject who has severely limited
capability for any activity<xref rid="r16" ref-type="bibr">16</xref><sup>)</sup>.</p><p>The BFMF was developed to evaluate the hand functions separately. It has 5 levels. At Level
I, one hand can be used without any restriction and there is restriction in the fine motor
skills of the other hand. At Level V, each hand can only hold at best<xref rid="r17" ref-type="bibr">17</xref><sup>)</sup>.</p><p>The Functional Independence Measure of children (WeeFIM) consists of 6 sub-categories.
There are a total of 18 items: 6 items of self-care, 2 items of sphincter control, 3 items
of transfer, 2 items of locomotion, 2 items of communication and 3 items of social
cognition. Each item is scored from 1 to 7, with 1 indicating full help and 7 indicating
full independence. The total score can range from a minimum of 18 to a maximum of 126<xref rid="r18" ref-type="bibr">18</xref><sup>)</sup>.</p><p>The Paediatric Quality of Life Scale (PedsQL) is a quality of life scale developed by Varni
et al. to measure the quality of life of chidren and adolescents aged 2&#x02013;18 years<xref rid="r19" ref-type="bibr">19</xref><sup>)</sup>. The areas of physical health, emotional
functionality and social functionality are surveyed as the characteristics of health status
defined by the World Health Organisation. Functionality at school is also surveyed. Scores
are calculated for three domains. First, the total points (MTP), then the physical health
total (PHTP), and finally the psychosocial health (PSHTP) are calculated from the item
scores evaluating emotional, social and school functionality<xref rid="r20" ref-type="bibr">20</xref><sup>)</sup>. The PedsQL is a quality of life scale consisting of 23 items which
is suitable for use for the general population, such as in schools or hospitals, for both
healthy and sick children and adolescents. The items are scored between 0&#x02013;100. A response of
never scores 100, rarely 75, sometimes 50, often 25 and always, 0. The higher the total
score in the PedsQL, the better the quality of life is perceived in relation to health<xref rid="r20" ref-type="bibr">20</xref><sup>)</sup>. Important properties of the PedsQL are
that it is short and can be completed in 5&#x02013;10 minutes, it can be conducted by a researcher
and the scoring is easy<xref rid="r20" ref-type="bibr">20</xref>, <xref rid="r21" ref-type="bibr">21</xref><sup>)</sup>. In the current study, the PedsQL children and parent
forms were used. Previous studies have been demonsrated on the validity and reliability of
the Turkish version of PedsQL for the 2&#x02013;18 years age group<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r24" ref-type="bibr">24</xref><sup>)</sup>.</p><p>Statistical analyses were carried out using SPSS 18.0 for Windows (PASW Statistics for
Windows, SPSS Inc., Chicago, Illinois, USA). Spearman correlation coefficients were used to
determine the relationships between variables. All demographic and quantitative data are
expressed as mean &#x000b1; standard deviation (SD). Differences with p values &#x0003c; 0.05 were
considered statistically significant and all results are expressed with a 95% confidence
interval. The overall agreement between each GMFCS, MACS and BFMF values were analyzed using
non-weighted Kappa statistics. Kappa values of &#x0003c;0.20 show poor agreement, 0.21&#x02013;0.40 fair,
0.41&#x02013;0.60 moderate, 0.61&#x02013;0.80 good, and &#x0003e;0.80 very good agreement<xref rid="r25" ref-type="bibr">25</xref>, <xref rid="r26" ref-type="bibr">26</xref><sup>)</sup>.</p></sec><sec sec-type="results" id="s3"><title>RESULTS</title><p>The study included 32 patients, 16 males and 16 females with a mean age of 90.50&#x000b1;31.60
months (range, 50&#x02013;172 months). Five (15.6%) of the patients were pre-term and 27 (84.4%)
were term. Six (18.8%) of the patients had a low birth-weight, 10 (32.3%) had epilepsy and
14 (43.8%) had a history of anoxia. Twenty-two (68.8%) patients were delivered by the normal
vaginal route, and 10 (31.3%) by caesarian section. The mean time of CP diagnosis was
12.96&#x000b1;9.41 months and the mean time to starting rehabilitation was 21.93&#x000b1;19.16 months.
WeeFIM, PedsQL scores, developmental evaluation, and the distribution of patients according
to GMFCS, BFMF and MACS are shown in <xref rid="tbl_001" ref-type="table">Table
1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Clinical characteristics of the patients</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Characteristic </th><th align="center" rowspan="1" colspan="1">Total, n=32<break/>n (%) </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Developmental evaluation</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Normal</td><td align="center" rowspan="1" colspan="1">14 (43.8)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Retarded </td><td align="center" rowspan="1" colspan="1">18 (56.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">WeeFIM total score, mean (SD)</td><td align="center" rowspan="1" colspan="1">77.87&#x000b1;45.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Child form of PedsQL, mean (SD)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">PedsQL total score </td><td align="center" rowspan="1" colspan="1">40.25&#x000b1;33.96</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">PedsQL physical score</td><td align="center" rowspan="1" colspan="1">40.40&#x000b1;33.25</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">PedsQL psychosocial score </td><td align="center" rowspan="1" colspan="1">40.41&#x000b1;35.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Parent form of PedsQL, mean (SD)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">PedsQL total score</td><td align="center" rowspan="1" colspan="1">43.44&#x000b1;31.51</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">PedsQL physical score</td><td align="center" rowspan="1" colspan="1">38.83&#x000b1;33.48</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">PedsQL psychosocial score</td><td align="center" rowspan="1" colspan="1">45.22&#x000b1;31.89</td></tr><tr><td align="left" rowspan="1" colspan="1">GMFCS, levels</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">16 (50)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">5 (15.6)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">9 (28.1)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">MACS, levels</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">10 (31.3)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">18 (56.3)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2 (6.3)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">BFMF, levels</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">18 (56.3)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">8 (25)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3 (9.4)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2 (6.3)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1 (3.1)</td></tr></tbody></table><table-wrap-foot><p>BFMF: Bimanual Fine Motor Function, GMFCS: Gross Motor Function Classification
System, MACS: Manual Ability Classification System, PedsQL: Paediatric Quality of Life
Scale, WeeFIM: The Functional Independence Measure of children</p></table-wrap-foot></table-wrap>.</p><p>Developmental evaluation of 25 (78.1%) patients was made using the ADSI. Of these 12 (48%)
were aged below 6&#x02005;years and 13 (52%) could not perform the age-appropriate test even though
they were aged over 6&#x02005;years. The distribution of the patients according to the ADSI test is
shown in <xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Distribution of the patients according to the ADSI test</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Total, n=25 </th><th valign="top" align="center" rowspan="1" colspan="1">ADSI-GD</th><th valign="top" align="center" rowspan="1" colspan="1">ADSI-CC</th><th valign="top" align="center" rowspan="1" colspan="1">ADSI-FM</th><th valign="top" align="center" rowspan="1" colspan="1">ADSI-GM</th><th valign="top" align="center" rowspan="1" colspan="1">ADSI-SC</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Normal, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (40)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (48)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (36)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (20)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (48)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Retarded, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (60)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (52)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (64)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (80)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (52)</td></tr></tbody></table><table-wrap-foot><p>ADSI: Ankara Developmental Screening Inventory, GD: general development, CC:
communication-cognitive, FM: fine motor, GM: gross motor, SC: social
skills-self-care</p></table-wrap-foot></table-wrap>. Of the 7 (21.9%) patients assessed using the WISC-R, 3 were evaluated as
retarded general development and 4 as normal development.</p><p>In the ophthalmology examination, biomicroscopy of 31 (96.9%) patients was normal. In 1
(3.1%) patient, bilateral aphakia and micro cornea were determined. Bilateral mixed type
astigmatism was determined in 2 (6.3%) patients and glaucomatous optic atrophy in 2 (6.3%)
patients. The findings of the ophthalmology examinations are shown in <xref rid="tbl_003" ref-type="table">Table 3</xref><table-wrap id="tbl_003" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Findings of the ophthalmology examinations</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Ophthalmological findings</th><th align="center" rowspan="1" colspan="1">Total, n=32<break/>n (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Biomicroscopic examination </td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Normal</td><td align="center" rowspan="1" colspan="1">31 (96.9)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Bilateral aphakia</td><td align="center" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Fundus examination </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Normal</td><td align="center" rowspan="1" colspan="1">25 (78.1)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Unilateral optic atrophy</td><td align="center" rowspan="1" colspan="1">2 (6.3)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Bilateral optic atrophy </td><td align="center" rowspan="1" colspan="1">3 (9.4)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Glaucomatous optic atrophy</td><td align="center" rowspan="1" colspan="1">2 (6.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Strabismus</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Exotropia</td><td align="center" rowspan="1" colspan="1">4 (12.5)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Esotropia </td><td align="center" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Refraction errors</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Normal</td><td align="center" rowspan="1" colspan="1">30 (93.8)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Mixed type astigmatism</td><td align="center" rowspan="1" colspan="1">2 (6.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Right eye intraocular pressure, mean&#x000b1;SD (range), mmHg</td><td align="center" rowspan="1" colspan="1">15.65&#x000b1;3.37 (11&#x02013;30)</td></tr><tr><td align="left" rowspan="1" colspan="1">Left eye intraocular pressure, mean&#x000b1;SD (range), mmHg</td><td align="center" rowspan="1" colspan="1">15.81&#x000b1;3.45 (11&#x02013;31)</td></tr></tbody></table></table-wrap>.</p><p>A significant positive correlation was determined between the GMFCS and BFMF scores
(r=0.636, p&#x0003c;0.001). The Kappa value was calculated and the overall agreement between the
GMFCS and BFMF was fair (Kappa value=0.288) (<xref rid="tbl_004" ref-type="table">Table
4</xref><table-wrap id="tbl_004" orientation="portrait" position="float"><label>Table 4.</label><caption><title>Distribution of GMFCS and BFMF levels</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="middle" align="left" colspan="1">GMFCS Levels</th><th valign="top" align="left" rowspan="1" colspan="1">BFMF levels</th><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><th colspan="6" rowspan="1"><hr/></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">1</th><th valign="top" align="center" rowspan="1" colspan="1">2</th><th valign="top" align="center" rowspan="1" colspan="1">3</th><th valign="top" align="center" rowspan="1" colspan="1">4</th><th valign="top" align="center" rowspan="1" colspan="1">5</th><th valign="top" align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">13 (40.6)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.4)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">16 (50)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.4)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">5 (15.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1) </td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.4)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (28.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="center" valign="top" rowspan="1" colspan="1">18 (56.3)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (25)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.4)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (100)</td></tr></tbody></table><table-wrap-foot><p>Kappa: 0.288 p=0.004. BFMF: Bimanual Fine Motor Function, GMFCS: Gross Motor Function
Classification System</p></table-wrap-foot></table-wrap>).</p><p>A significant positive correlation was determined between the GMFCS and MACS scores
(r=0.553, p=0.001). The Kappa value was calculated and the overall agreement between the
GMFCS and MACS was fair (Kappa value=0.202) (<xref rid="tbl_005" ref-type="table">Table
5</xref><table-wrap id="tbl_005" orientation="portrait" position="float"><label>Table 5.</label><caption><title>Distribution of GMFCS and MACS levels</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="middle" align="left" colspan="1">GMFCS Levels</th><th valign="top" align="left" rowspan="1" colspan="1">MACS levels</th><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><th colspan="6" rowspan="1"><hr/></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">1</th><th valign="top" align="center" rowspan="1" colspan="1">2</th><th valign="top" align="center" rowspan="1" colspan="1">3</th><th valign="top" align="center" rowspan="1" colspan="1">4</th><th valign="top" align="left" rowspan="1" colspan="1">5</th><th valign="top" align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">8 (25)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (25)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">16 (50)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.4)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">5 (15.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">6 (18.8)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (28.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="center" valign="top" rowspan="1" colspan="1">10 (31.3)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (56.3)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (100)</td></tr></tbody></table><table-wrap-foot><p>Kappa=0.202 p=0.018. GMFCS: Gross Motor Function Classification System, MACS: Manual
Ability Classification System</p></table-wrap-foot></table-wrap>).</p><p>A significant positive correlation was determined between the MACS and BFMF scores
(r=0.718, p&#x0003c;0.001). The Kappa value was calculated and the overall agreement between the
MACS and BFMF was moderate (Kappa value=0.537) (<xref rid="tbl_006" ref-type="table">Table
6</xref><table-wrap id="tbl_006" orientation="portrait" position="float"><label>Table 6.</label><caption><title>Distribution of BFMF and MACS levels</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="middle" align="left" colspan="1">BFMF levels</th><th valign="top" align="left" rowspan="1" colspan="1">MACS levels</th><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><th colspan="6" rowspan="1"><hr/></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">1</th><th valign="top" align="center" rowspan="1" colspan="1">2</th><th valign="top" align="center" rowspan="1" colspan="1">3</th><th valign="top" align="center" rowspan="1" colspan="1">4</th><th valign="top" align="center" rowspan="1" colspan="1">5</th><th valign="top" align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">10 (31.3)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (25)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">18 (56.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">8 (25)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">8 (25)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="center" valign="top" rowspan="1" colspan="1">10 (31.3)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (56.3)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (100)</td></tr></tbody></table><table-wrap-foot><p>Kappa= 0.537 p&#x0003c;0.001. BFMF: Bimanual Fine Motor Function, MACS: Manual Ability
Classification System</p></table-wrap-foot></table-wrap>).</p><p>The relationships between ocular and oculomotor disorders, GMFCS, BFMF and MACS and daily
life activities and quality of life are shown in <xref rid="tbl_007" ref-type="table">Table
7</xref><table-wrap id="tbl_007" orientation="portrait" position="float"><label>Table 7.</label><caption><title>Correlation among oculomotor disorders, GMFCS, BFMF and MACS, WeeFIM and quality
of life</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Total cases (n=32)</th><th align="center" valign="middle" rowspan="1" colspan="1">WeeFIM</th><th valign="top" align="center" rowspan="1" colspan="1">PedsQL-<break/>MTP-CF</th><th valign="top" align="center" rowspan="1" colspan="1">PedsQL-<break/>PHTP-CF</th><th valign="top" align="center" rowspan="1" colspan="1">PedsQL-<break/>PSHTP-CF</th><th valign="top" align="center" rowspan="1" colspan="1">PedsQL-<break/>MTP-PF</th><th valign="top" align="center" rowspan="1" colspan="1">PedsQL-<break/>PHTP-PF</th><th valign="top" align="center" rowspan="1" colspan="1">PedsQL-<break/>PSHTP-</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">GMFCS</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.802**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.788**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.836**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.789**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.788**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.844**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.710**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BFMF</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.769**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.693**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.661**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.685**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.729**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.712**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.668**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MACS</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.765**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.806**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.715**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.803**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.864**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.765**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.859**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fundus pathology</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.128</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.008</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.079</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.050</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.139</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.109</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.156</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Strabismus</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.220</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.297</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.312</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.284</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.191</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.300</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.168</td></tr></tbody></table><table-wrap-foot><p>**Correlation is significant at the 0.01 level (two-tailed). BFMF: Bimanual Fine
Motor Function, CF: Child form, MACS: Manual Ability Classification System, GMFCS:
Gross Motor Function Classification System, MTP: measured total points, PF: Parent
form, PedsQL: Paediatric Quality of Life Scale, PHTP: physical health total points,
PSHTP: psychosocial health total points</p></table-wrap-foot></table-wrap>. The relationships between general development, ADSI evaluation, ocular and
oculomotor disorders, GMFCS, BFMF and MACS and daily living activities and quality of life
are shown in <xref rid="tbl_008" ref-type="table">Table 8</xref><table-wrap id="tbl_008" orientation="portrait" position="float"><label>Table 8.</label><caption><title>Correlation of the developmental level with oculomotor disorders, GMFCS, BFMF,
MACS, WeeFIM and quality of life scores</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">ADSI-GD<break/>n=25</th><th valign="middle" align="center" rowspan="1" colspan="1">ADSI-CC<break/>n=25</th><th valign="middle" align="center" rowspan="1" colspan="1">ADSI-FM<break/>n=25</th><th valign="middle" align="center" rowspan="1" colspan="1">ADSI-GM<break/>n=25</th><th valign="middle" align="center" rowspan="1" colspan="1">ADSI-SC<break/>n=25</th><th valign="middle" align="center" rowspan="1" colspan="1">General<break/>development<break/>n=32</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">GMFCS</td><td align="center" valign="top" rowspan="1" colspan="1">0.612**</td><td align="center" valign="top" rowspan="1" colspan="1">0.756**</td><td align="center" valign="top" rowspan="1" colspan="1">0.556**</td><td align="center" valign="top" rowspan="1" colspan="1">0.262</td><td align="center" valign="top" rowspan="1" colspan="1">0.756**</td><td align="center" valign="top" rowspan="1" colspan="1">0.518**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BFMF</td><td align="center" valign="top" rowspan="1" colspan="1">0.675**</td><td align="center" valign="top" rowspan="1" colspan="1">0.590**</td><td align="center" valign="top" rowspan="1" colspan="1">0.726**</td><td align="center" valign="top" rowspan="1" colspan="1">0.201</td><td align="center" valign="top" rowspan="1" colspan="1">0.590**</td><td align="center" valign="top" rowspan="1" colspan="1">0.646**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MACS</td><td align="center" valign="top" rowspan="1" colspan="1">0.490*</td><td align="center" valign="top" rowspan="1" colspan="1">0.468*</td><td align="center" valign="top" rowspan="1" colspan="1">0.507**</td><td align="center" valign="top" rowspan="1" colspan="1">0.300</td><td align="center" valign="top" rowspan="1" colspan="1">0.468*</td><td align="center" valign="top" rowspan="1" colspan="1">0.537**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WeeFIM</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.700**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.720**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.691**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.279</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.764**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.645**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PedsQL- MTP-CF</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.645**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.791**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.552**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.296</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.762**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.669**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PedsQL- PHTP -CF</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.597**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.768**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.503**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.213</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.711**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.631**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PedsQL- PSHTP -CF</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.632**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.802**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.562**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.241</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.768**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.679**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PedsQL- MTP-PF</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.691**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.789**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.659**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.264</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.756**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.710**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PedsQL- PHTP -PF</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.743**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.838**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.657**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.215</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.786**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.754**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PedsQL- PSHTP -PF</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.573**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.695**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.642**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.236</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.651**</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.629**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fundus pathology</td><td align="center" valign="top" rowspan="1" colspan="1">0.134</td><td align="center" valign="top" rowspan="1" colspan="1">0.201</td><td align="center" valign="top" rowspan="1" colspan="1">0.327</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.055</td><td align="center" valign="top" rowspan="1" colspan="1">0.201</td><td align="center" valign="top" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Strabismus</td><td align="center" valign="top" rowspan="1" colspan="1">0.000</td><td align="center" valign="top" rowspan="1" colspan="1">0.080</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.042</td><td align="center" valign="top" rowspan="1" colspan="1">0.000</td><td align="center" valign="top" rowspan="1" colspan="1">0.080</td><td align="center" valign="top" rowspan="1" colspan="1">0.033</td></tr></tbody></table><table-wrap-foot><p>**Correlation is significant at the 0.01 level (two-tailed). ADSI: Ankara
Developmental Screening Inventory, BFMF: Bimanual Fine Motor Function, CC:
communication-cognitive, CF: Child form, FM: fine motor, GD: general development, GM:
gross motor, GMFCS: Gross Motor Function Classification System, MACS: Manual Ability
Classification System, MTP: measured total points, PF: Parent form, PedsQL: Paediatric
Quality of Life Scale, PHTP: physical health total points, PSHTP: psychosocial health
total points, SC: social skills-self-care</p></table-wrap-foot></table-wrap>.</p></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>This study found a significant relationship between developmental retardation in CP
patients and disease severity, hand functions, daily living activities and quality of life.
We also determined that MACS and BFMF conform with each other and with the severity of CP,
and that as CP severity increases, hand skills worsen.</p><p>It has been reported that BFMF is used more to define disability and MACS to evaluate
activity although it is stated that it is difficult to compare these two scales<xref rid="r26" ref-type="bibr">26</xref><sup>)</sup>. Another study reported a strong positive
correlation between BFMF and MACS with good overall agreement<xref rid="r10" ref-type="bibr">10</xref><sup>)</sup>. In the present study, a strong positive correlation was determined
between BFMF and MACS. The overall agreement between MACS and BFMF was moderate. In
addition, a strong correlation was found between GMFCS and BFMF, and GMFCS and MACS. The
overall agreement was fair, a result that is consistent with previous studies<xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r26" ref-type="bibr">26</xref>, <xref rid="r27" ref-type="bibr">27</xref><sup>)</sup>. Although the corrrelations between the
scales were high, the reason for low overall agreement, which was calculated using the Kappa
statistic, is that the Kappa statistic is a method which is actually used in the evaluation
of the same scale by two different researchers. For the evaluation of the agreement of two
different scales, using the correlation coefficient is more appropriate<xref rid="r25" ref-type="bibr">25</xref><sup>)</sup>. There is a lower rate of upper extremity involvement in
children with CP, so the low agreement found by the present study could be due to the
evaluation of only diplegic CP children.</p><p>In the present study, a significant relationship was shown between all the subscales of the
WeeFIM and PedsQL scales with each of the GMFCS, MACS and BFMF scales. In a study which
evaluated the relationships between WeeFIM and GMFCS and MACS in spastic CP patients,
significant correlations were determined between the latter two scales and WeeFIM, similar
to the results of our present<xref rid="r27" ref-type="bibr">27</xref><sup>)</sup>. As an
explanation for these results, we consider that as CP severity increases, hand functions are
impaired with deteriorations in daily living activities and quality of life.</p><p>The visual process is a complex cerebral activity which involves a large part of the
central nervous system<xref rid="r28" ref-type="bibr">28</xref><sup>)</sup>. It can be
considered, therefore that visual deficits are often seen in the neurodevelopmental
disabilities which are observed in CP. In CP patients with hypoxic ischaemia encephalopathy,
not only the motor pathways, but also the visual pathways are affected<xref rid="r29" ref-type="bibr">29</xref><sup>)</sup>. Fundus pathologies associated with the trans-synaptic
degeneration mechanism may develop in such patients<xref rid="r30" ref-type="bibr">30</xref><sup>)</sup>. In support of this view, a MRI study of CP children with visual
problems showed trans-synaptic degeneration of the lateral geniculate body<xref rid="r31" ref-type="bibr">31</xref><sup>)</sup>. Studies have also shown there is a
relationship between the severity of visual sensory problems in children with CP and mental
motor deficits<xref rid="r6" ref-type="bibr">6</xref>, <xref rid="r8" ref-type="bibr">8</xref>, <xref rid="r32" ref-type="bibr">32</xref><sup>)</sup>. Therefore, early
referral of CP children to an ophthalmologist can be an important factor in increasing
mental and motor capacity. In the present study, fundus pathology was determined in 21.9%,
strabismus in 15.6% and refractive error in 6.3% of patients. However, no significant
correlations were determined between the functional status, quality of life and
developmental level of CP patients with fundus pathology or strabismus. Cerebral visual
impairment is defined as the involvement of the retrogeniculate pathways in symptoms such as
reduced visual field and visual acuity. It has been determined in 60&#x02013;70% of children with
CP<xref rid="r33" ref-type="bibr">33</xref><sup>)</sup>. In the present study, cerebral
visual impairment in children with CP was not evaluated. Therefore, a significant
corrrelation may not have been revealed between oculomotor dysfunction and functional
status, quality of life and developmental level in children without oculomotor dysfunction
who may have visual problems.</p><p>In the present study, significant correlations were determined between general
developmental level and the functional status and quality of life of the children. In
children evaluated with the ADSI, significant relationships were also determined between
functional status and quality of life and all the subscales of ADSI except the ADSI-GM
subscale. The motivation of the children and general developmental levels may affect hand
skills. Therefore, when there is a poor functional status in children with good general
development and high capacity expectations, motivational factors can be considered to be
exerting an effect and different treatment strategies should be defined.</p><p>Limitations of the present study were the inclusion of only diplegic type spastic CP
patients, and the lack of evaluation of cerebral visual impairment, visuocognitive
dysfunction or visuoperceptual diseases in the ophthalmology examination.</p><p>In conclusion, GMFCS, MACS and BFMF can be useful in the determination of the functional
status of children with CP as they are easy, practical and simple classification scales
which are consistent with each other. Ophthalmological examination of children with CP in
the early period and early treatment strategies may enhance the possibility of increasing
the mental and motor development of these children. However, there is a need for further
larger studies with detailed neuro-ophthalmological evaluation including CP patients with
different clinical characteristics.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Song</surname><given-names>CS</given-names></name></person-group>: <article-title>Relationships between physical and cognitive functioning
and activities of daily living in children with cerebral palsy</article-title>.
<source>J Phys Ther Sci</source>, <year>2013</year>, <volume>25</volume>:
<fpage>619</fpage>&#x02013;<lpage>622</lpage>. <pub-id pub-id-type="pmid">24259815</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Rosenbaum</surname><given-names>P</given-names></name><name><surname>Paneth</surname><given-names>N</given-names></name><name><surname>Leviton</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>: <article-title>A report: the definition and classification of cerebral
palsy April 2006</article-title>. <source>Dev Med Child Neurol Suppl</source>,
<year>2007</year>, <volume>109</volume>: <fpage>8</fpage>&#x02013;<lpage>14</lpage>.
<pub-id pub-id-type="pmid">17370477</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Serdaro&#x0011f;lu</surname><given-names>A</given-names></name><name><surname>Cansu</surname><given-names>A</given-names></name><name><surname>Ozkan</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>: <article-title>Prevalence of cerebral palsy in Turkish children between
the ages of 2 and 16 years</article-title>. <source>Dev Med Child Neurol</source>,
<year>2006</year>, <volume>48</volume>: <fpage>413</fpage>&#x02013;<lpage>416</lpage>.
<pub-id pub-id-type="pmid">16700929</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Odding</surname><given-names>E</given-names></name><name><surname>Roebroeck</surname><given-names>ME</given-names></name><name><surname>Stam</surname><given-names>HJ</given-names></name></person-group>: <article-title>The epidemiology of cerebral palsy: incidence, impairments
and risk factors</article-title>. <source>Disabil Rehabil</source>, <year>2006</year>,
<volume>28</volume>: <fpage>183</fpage>&#x02013;<lpage>191</lpage>. <pub-id pub-id-type="pmid">16467053</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Pennefather</surname><given-names>PM</given-names></name><name><surname>Tin</surname><given-names>W</given-names></name></person-group>: <article-title>Ocular abnormalities associated with cerebral palsy after
preterm birth</article-title>. <source>Eye (Lond)</source>, <year>2000</year>,
<volume>14</volume>: <fpage>78</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="pmid">10755106</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Black</surname><given-names>P</given-names></name></person-group>: <article-title>Visual disorders associated with cerebral
palsy</article-title>. <source>Br J Ophthalmol</source>, <year>1982</year>,
<volume>66</volume>: <fpage>46</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="pmid">7055543</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Grether</surname><given-names>JK</given-names></name><name><surname>Cummins</surname><given-names>SK</given-names></name><name><surname>Nelson</surname><given-names>KB</given-names></name></person-group>: <article-title>The california cerebral palsy project</article-title>.
<source>Paediatr Perinat Epidemiol</source>, <year>1992</year>, <volume>6</volume>:
<fpage>339</fpage>&#x02013;<lpage>351</lpage>. <pub-id pub-id-type="pmid">1635884</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Kozeis</surname><given-names>N</given-names></name><name><surname>Anogeianaki</surname><given-names>A</given-names></name><name><surname>Mitova</surname><given-names>DT</given-names></name><etal>et al.</etal></person-group>: <article-title>Visual function and visual perception in cerebral palsied
children</article-title>. <source>Ophthalmic Physiol Opt</source>, <year>2007</year>,
<volume>27</volume>: <fpage>44</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="pmid">17239189</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Ozturk</surname><given-names>AT</given-names></name><name><surname>Berk</surname><given-names>AT</given-names></name><name><surname>Yaman</surname><given-names>A</given-names></name></person-group>: <article-title>Ocular disorders in children with spastic subtype of
cerebral palsy</article-title>. <source>Int J Ophthalmol</source>, <year>2013</year>,
<volume>6</volume>: <fpage>204</fpage>&#x02013;<lpage>210</lpage>. <pub-id pub-id-type="pmid">23638425</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Kurt</surname><given-names>EE</given-names></name><name><surname>Unsal Delialioglu</surname><given-names>S</given-names></name><name><surname>Ozel</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>: <article-title>Evaluation of the relation between hand functions and
severity of cerebral palsy</article-title>. <source>Turkiye Fiziksel Tip Ve
Rehabilitasyon Dergisi-Turkish J Phys Med Rehabil</source>, <year>2013</year>,
<volume>59</volume>: <fpage>18</fpage>&#x02013;<lpage>25</lpage>.</mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Hagberg</surname><given-names>B</given-names></name><name><surname>Hagberg</surname><given-names>G</given-names></name><name><surname>Olow</surname><given-names>I</given-names></name></person-group>: <article-title>The changing panorama of cerebral palsy in Sweden
1954</article-title>&#x02013;<article-title>1970. I. Analysis of the general
changes</article-title>. <source>Acta Paediatr Scand</source>, <year>1975</year>,
<volume>64</volume>: <fpage>187</fpage>&#x02013;<lpage>192</lpage>. </mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="book"><person-group><name><surname>Savas&#x00131;r</surname><given-names>I</given-names></name><name><surname>Sezgin</surname><given-names>N</given-names></name><name><surname>Erol</surname><given-names>N</given-names></name></person-group>: Ankara developmental screening inventory [Ankara gelisim tarama
envanteri-agte], 3rd ed. Ankara: Turkish psychology association Pub,
<year>2005</year>.</mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Erol</surname><given-names>N</given-names></name><name><surname>Sezgin</surname><given-names>N</given-names></name><name><surname>Sava&#x0015f;&#x00131;r</surname><given-names>I</given-names></name></person-group>: <article-title>Geli&#x0015f;im tarama envanteri ile ilgili ge&#x000e7;erlik
&#x000e7;al&#x00131;&#x0015f;malar&#x00131;</article-title>. <source>Turk Psikoloji Dergisi</source>, <year>1994</year>,
<volume>8</volume>: <fpage>16</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Sezgin</surname><given-names>N</given-names></name><name><surname>Erol</surname><given-names>N</given-names></name><name><surname>Sava&#x0015f;&#x00131;r</surname><given-names>I</given-names></name></person-group>: <article-title>0&#x02013;6 ya&#x0015f; &#x000e7;ocuklar&#x00131; i&#x000e7;in geli&#x0015f;im tarama
envanteri</article-title>. <source>Turk Psikiyatri Derg</source>, <year>1993</year>,
<volume>4</volume>: <fpage>9</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Palisano</surname><given-names>R</given-names></name><name><surname>Rosenbaum</surname><given-names>P</given-names></name><name><surname>Walter</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>: <article-title>Development and reliability of a system to classify gross
motor function in children with cerebral palsy</article-title>. <source>Dev Med Child
Neurol</source>, <year>1997</year>, <volume>39</volume>:
<fpage>214</fpage>&#x02013;<lpage>223</lpage>. <pub-id pub-id-type="pmid">9183258</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Eliasson</surname><given-names>AC</given-names></name><name><surname>Krumlinde-Sundholm</surname><given-names>L</given-names></name><name><surname>R&#x000f6;sblad</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>: <article-title>The Manual Ability Classification System (MACS) for
children with cerebral palsy: scale development and evidence of validity and
reliability</article-title>. <source>Dev Med Child Neurol</source>, <year>2006</year>,
<volume>48</volume>: <fpage>549</fpage>&#x02013;<lpage>554</lpage>. <pub-id pub-id-type="pmid">16780622</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Beckung</surname><given-names>E</given-names></name><name><surname>Hagberg</surname><given-names>G</given-names></name></person-group>: <article-title>Neuroimpairments, activity limitations, and participation
restrictions in children with cerebral palsy</article-title>. <source>Dev Med Child
Neurol</source>, <year>2002</year>, <volume>44</volume>:
<fpage>309</fpage>&#x02013;<lpage>316</lpage>. <pub-id pub-id-type="pmid">12033716</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Ottenbacher</surname><given-names>KJ</given-names></name><name><surname>Msall</surname><given-names>ME</given-names></name><name><surname>Lyon</surname><given-names>NR</given-names></name><etal>et al.</etal></person-group>: <article-title>Interrater agreement and stability of the Functional
Independence Measure for Children (WeeFIM): use in children with developmental
disabilities</article-title>. <source>Arch Phys Med Rehabil</source>, <year>1997</year>,
<volume>78</volume>: <fpage>1309</fpage>&#x02013;<lpage>1315</lpage>. <pub-id pub-id-type="pmid">9421983</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Varni</surname><given-names>JW</given-names></name><name><surname>Seid</surname><given-names>M</given-names></name><name><surname>Rode</surname><given-names>CA</given-names></name></person-group>: <article-title>The PedsQL: measurement model for the pediatric quality of
life inventory</article-title>. <source>Med Care</source>, <year>1999</year>,
<volume>37</volume>: <fpage>126</fpage>&#x02013;<lpage>139</lpage>. <pub-id pub-id-type="pmid">10024117</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Varni</surname><given-names>JW</given-names></name><name><surname>Seid</surname><given-names>M</given-names></name><name><surname>Kurtin</surname><given-names>PS</given-names></name></person-group>: <article-title>PedsQL 4.0: reliability and validity of the Pediatric
Quality of Life Inventory version 4.0 generic core scales in healthy and patient
populations</article-title>. <source>Med Care</source>, <year>2001</year>,
<volume>39</volume>: <fpage>800</fpage>&#x02013;<lpage>812</lpage>. <pub-id pub-id-type="pmid">11468499</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Eiser</surname><given-names>C</given-names></name><name><surname>Morse</surname><given-names>R</given-names></name></person-group>: <article-title>Quality-of-life measures in chronic diseases of
childhood</article-title>. <source>Health Technol Assess</source>, <year>2001</year>,
<volume>5</volume>: <fpage>1</fpage>&#x02013;<lpage>157</lpage>. <pub-id pub-id-type="pmid">11262421</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Cakin Memik</surname><given-names>N</given-names></name><name><surname>A&#x0011f;ao&#x0011f;lu</surname><given-names>B</given-names></name><name><surname>Co&#x0015f;kun</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>: <article-title>[The validity and reliability of the Turkish Pediatric
Quality of Life Inventory for children 13</article-title>&#x02013;<article-title>18 years
old]</article-title>. <source>Turk Psikiyatri Derg</source>, <year>2007</year>,
<volume>18</volume>: <fpage>353</fpage>&#x02013;<lpage>363</lpage>. </mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>Uneri</surname><given-names>OS</given-names></name><name><surname>Agaoglu</surname><given-names>B</given-names></name><name><surname>Coskun</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>: <article-title>Validity and reliability of Pediatric Quality of Life
Inventory for 2- to 4-year-old and 5- to 7-year-old Turkish children</article-title>.
<source>Qual Life Res</source>, <year>2008</year>, <volume>17</volume>:
<fpage>307</fpage>&#x02013;<lpage>315</lpage>. <pub-id pub-id-type="pmid">18205028</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Memik</surname><given-names>NC</given-names></name><name><surname>Agaoglu</surname><given-names>B</given-names></name><name><surname>Coskun</surname><given-names>A</given-names></name><etal>et al</etal></person-group>: &#x000c7;ocuklar &#x00130;&#x000e7;in ya&#x0015f;am kalitesi &#x000f6;l&#x000e7;e&#x0011f;inin 8&#x02013;12 ya&#x0015f; &#x000e7;ocuk formunun ge&#x000e7;erlik
ve g&#x000fc;venirli&#x0011f;i. &#x000c7;ocuk ve Ergen Ruh Sa&#x0011f;l&#x00131;&#x0011f;&#x00131; Dergisi, <year>2008</year>:
87&#x02013;98.</mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="book"><person-group><name><surname>Altman</surname><given-names>DG</given-names></name></person-group>: Practical statistics for medical research. London: Chapman and Hall,
<year>1991</year>.</mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Carnahan</surname><given-names>KD</given-names></name><name><surname>Arner</surname><given-names>M</given-names></name><name><surname>H&#x000e4;gglund</surname><given-names>G</given-names></name></person-group>: <article-title>Association between gross motor function (GMFCS) and
manual ability (MACS) in children with cerebral palsy. A population-based study of 359
children</article-title>. <source>BMC Musculoskelet Disord</source>, <year>2007</year>,
<volume>8</volume>: <fpage>50</fpage>. <pub-id pub-id-type="pmid">17584944</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name><surname>Gunel</surname><given-names>MK</given-names></name><name><surname>Mutlu</surname><given-names>A</given-names></name><name><surname>Tarsuslu</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>: <article-title>Relationship among the Manual Ability Classification
System (MACS), the Gross Motor Function Classification System (GMFCS), and the
functional status (WeeFIM) in children with spastic cerebral palsy</article-title>.
<source>Eur J Pediatr</source>, <year>2009</year>, <volume>168</volume>:
<fpage>477</fpage>&#x02013;<lpage>485</lpage>. <pub-id pub-id-type="pmid">18551314</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group><name><surname>Dutton</surname><given-names>GN</given-names></name><name><surname>McKillop</surname><given-names>EC</given-names></name><name><surname>Saidkasimova</surname><given-names>S</given-names></name></person-group>: <article-title>Visual problems as a result of brain damage in
children</article-title>. <source>Br J Ophthalmol</source>, <year>2006</year>,
<volume>90</volume>: <fpage>932</fpage>&#x02013;<lpage>933</lpage>. <pub-id pub-id-type="pmid">16854832</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group><name><surname>Dutton</surname><given-names>GN</given-names></name><name><surname>Jacobson</surname><given-names>LK</given-names></name></person-group>: <article-title>Cerebral visual impairment in children</article-title>.
<source>Semin Neonatol</source>, <year>2001</year>, <volume>6</volume>:
<fpage>477</fpage>&#x02013;<lpage>485</lpage>. <pub-id pub-id-type="pmid">12014888</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group><name><surname>Ruberto</surname><given-names>G</given-names></name><name><surname>Salati</surname><given-names>R</given-names></name><name><surname>Milano</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>: <article-title>Changes in the optic disc excavation of children affected
by cerebral visual impairment: a tomographic analysis</article-title>. <source>Invest
Ophthalmol Vis Sci</source>, <year>2006</year>, <volume>47</volume>:
<fpage>484</fpage>&#x02013;<lpage>488</lpage>. <pub-id pub-id-type="pmid">16431940</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group><name><surname>Uggetti</surname><given-names>C</given-names></name><name><surname>Egitto</surname><given-names>MG</given-names></name><name><surname>Fazzi</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>: <article-title>Transsynaptic degeneration of lateral geniculate bodies in
blind children: in vivo MR demonstration</article-title>. <source>AJNR Am J
Neuroradiol</source>, <year>1997</year>, <volume>18</volume>:
<fpage>233</fpage>&#x02013;<lpage>238</lpage>. <pub-id pub-id-type="pmid">9111657</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group><name><surname>Ghasia</surname><given-names>F</given-names></name><name><surname>Brunstrom</surname><given-names>J</given-names></name><name><surname>Gordon</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>: <article-title>Frequency and severity of visual sensory and motor
deficits in children with cerebral palsy: gross motor function classification
scale</article-title>. <source>Invest Ophthalmol Vis Sci</source>, <year>2008</year>,
<volume>49</volume>: <fpage>572</fpage>&#x02013;<lpage>580</lpage>. <pub-id pub-id-type="pmid">18235001</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group><name><surname>Schenk-Rootlieb</surname><given-names>AJ</given-names></name><name><surname>van Nieuwenhuizen</surname><given-names>O</given-names></name><name><surname>van Waes</surname><given-names>PF</given-names></name><etal>et al.</etal></person-group>: <article-title>Cerebral visual impairment in cerebral palsy: relation to
structural abnormalities of the cerebrum</article-title>.
<source>Neuropediatrics</source>, <year>1994</year>, <volume>25</volume>:
<fpage>68</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="pmid">8072677</pub-id></mixed-citation></ref></ref-list></back></article>
